Form 4: Senti Biosciences Director Brenda Cooperstone Granted Stock Options

Senti Biosciences, Inc. Director Brenda Cooperstone was granted 21,950 stock options with an exercise price of $2.05, vesting over one year or by the 2026 Annual Meeting.

Summary

• Brenda Cooperstone, a Director of Senti Biosciences, Inc. (SNTI), was granted 21,950 stock options.
• The stock options have an exercise price of $2.05 per share.
• The options will vest 100% upon the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the 2026 Annual Meeting, contingent on her continued service.
• The options are set to expire on June 24, 2035.
• Following this transaction, Ms. Cooperstone directly beneficially owns 21,950 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine equity grant to a director, which is a standard compensation practice that aligns interests. It does not indicate any significant positive or negative operational or financial news for the company.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• Equity compensation is a common method used by companies to attract and retain qualified board members.

Negatives

• The options have no immediate cash value, and their ultimate value is contingent on the future performance of Senti Biosciences' stock price exceeding the $2.05 exercise price.
• Vesting of the options is subject to the director's continued service, meaning the benefit is not guaranteed if service is terminated prematurely.

Risks

• The value of the stock options is subject to the inherent volatility and market risks associated with Senti Biosciences' common stock.
• There is a risk that the company's stock price may not exceed the exercise price of $2.05, which would render the options worthless.
• The vesting of the options is contingent on the director's continued service, posing a risk if service is terminated before the vesting conditions are met.

Future Outlook

The future value of these options is directly tied to Senti Biosciences' stock performance. The options are expected to vest by mid-2026, subject to the director's continued service, allowing for potential future exercise and realization of value.

Industry Context

Granting stock options to non-employee directors is a standard practice across many industries, particularly in biotechnology, to align their interests with long-term shareholder value and to compensate them for their oversight and strategic guidance.

Comparison to Industry Standards

• Equity compensation, such as stock options, for non-executive directors is a common practice in the biotechnology sector and broader public markets.
• While specific grant sizes vary by company size, stage, and individual director responsibilities, the mechanism itself is standard.
• Similar grants are observed at comparable early-stage biotech firms like Ginkgo Bioworks (DNA) or Editas Medicine (EDIT) for their board members, aiming to incentivize long-term commitment and performance.

Corporate Governance

Related Party Transactions

• This transaction represents an equity grant to a director, which is considered a related-party transaction. However, it is a standard form of compensation for board service, disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing stock value.
• Employees: No direct impact on employees is indicated by this specific filing.
• Management: No direct impact on management is indicated by this specific filing.

Next Steps

• The stock options will vest upon the earlier of the first anniversary of the grant date or the 2026 Annual Meeting, subject to continued service.
• Upon vesting, the director will have the right to exercise the options to purchase common stock at the specified exercise price until the expiration date.

Key Dates

Keywords

Senti Biosciences, SNTI, stock option, director, insider transaction, Form 4, equity grant, Brenda Cooperstone, compensation